Lymphoma, large b-cell, diffuse Trials in Shanghai, China
Conditions / Lymphoma, large b-cell, diffuse / Shanghai, China
Lymphoma, large b-cell, diffuse has been the subject of sustained clinical investigation across multiple research sites.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06093841 | Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT03373019 | Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | UNKNOWN | PHASE2 |
| NCT06852638 | CD70-targeted immunoPET Imaging of Malignant Cancers | RECRUITING | NA |
| NCT05923879 | Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma | UNKNOWN | — |
| NCT05318391 | Translational Study of Molecular Classification of Relapsed/Refractory Diffuse Large B-cell Lymphoma | COMPLETED | — |
| NCT02285062 | Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma | COMPLETED | PHASE3 |
| NCT04799314 | PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT | UNKNOWN | PHASE3 |
| NCT04849416 | A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) | COMPLETED | PHASE2 |
| NCT04789434 | PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT | UNKNOWN | PHASE3 |
| NCT03600363 | A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients | UNKNOWN | PHASE2 |